(Reuters) - Alnylam Pharmaceuticals Inc's experimental drug to treat a type of respiratory infection in lung transplant patients missed the main goal of a mid-stage trial. The drug, codenamed ALN-RSV01, is being developed to treat respiratory syncytial virus (RSV) infection that causes respiratory illness in young children. "We have questioned the investment in this trial since before it even ...
